Kenyan Pharmaceutical Company Achieves Landmark WHO Approval for Malaria Drug Production

In a groundbreaking development, Universal Corporation Limited, a Kenyan pharmaceutical company, has received approval from the World Health Organisation (WHO) to manufacture the essential antimalarial drug sulfadoxine-pyrimethamine plus amodiaquine (Spaq). This milestone makes Universal Corporation Limited the first African manufacturer to gain WHO approval for a lifesaving malaria drug.

Spaq is widely used to prevent seasonal malaria in children during peak transmission periods like rainy seasons. Previously, Africa relied heavily on imported generic versions of the medicine from countries like India and China. Over 70% of drugs used in Africa are imported, and only a handful of pharmaceutical companies in Africa hold WHO “prequalified” status, indicating adherence to international standards in manufacturing processes and quality control.

This achievement holds immense significance, representing a move towards reducing Africa’s dependency on imported drugs and strengthening the continent’s self-sufficiency in providing crucial healthcare solutions. The approval empowers Universal Corporation Limited to enter new markets, making locally produced drugs accessible to more people and facilitating the fight against malaria.

Drugs like Spaq are vital in the battle against malaria, particularly for children under five, who account for nearly 80% of malaria deaths in Africa. The affordability and accessibility of Spaq bolster self-sufficiency in malaria control, reducing reliance on external aid and allowing resources to be strategically allocated to combat this devastating disease comprehensively.

This milestone aligns with the urgent need for Africa to enhance its local production capacity, as underscored by disruptions in drug distribution during the Covid pandemic. Efforts such as the African Continental Free Trade Area are crucial, removing trade barriers and enabling the trade of manufactured medicines within the region. With continued support from governments, procurement agencies, and stakeholders, millions of lives, especially those of children and pregnant women in Africa, can be safeguarded from malaria.